FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890802034> ?p ?o ?g. }

• W2890802034 endingPage "319" @default.
• W2890802034 startingPage "307" @default.
• W2890802034 abstract "Abstract Background The aim of the study was to analyze the overall survival (OS) and progression free survival (PFS) of patients with high grade and advanced stage epithelial ovarian cancer (EOC) with at least 60 months of follow-up treated in a single gynecologic oncology institute. We compared primary debulking surgery (PDS) versus neoadjuvant chemotherapy plus interval debulking surgery (NACT + IDS) stratifying data based on residual disease with the intent to identify the rationale for therapeutic option decision and the role of laparoscopic evaluation of resectability for that intention. Patients and methods This is observational retrospective study on consecutive patients with diagnosis of high grade and International Federation of Gynecology and Obstetrics (FIGO) stage III/IV EOC referred to our center between January 2008 and May 2012. We selected only patients with a follow-up of at least 60 months. Primary endpoint was to compare PDS versus NACT + IDS in term of progression free survival (PFS) and overall survival (OS). Secondary endpoints were PFS and OS stratifying data according to residual disease after surgery in patients receiving PDS versus NACT + IDS. Finally, through Cox hazards models, we tested the prognostic value of different variables (patient age at diagnosis, residual disease after debulking, American Society of Anesthesiologists (ASA) stage, number of adjuvant-chemotherapy cycles) for predicting OS. Results A total number of 157 patients were included in data analysis. Comparing PDS arm (108 patients) and NACT + IDS arm (49 patients) we found no significant differences in term of OS (41.3 versus 34.5 months, respectively) and PFS (17.3 versus 18.3 months, respectively). According to residual disease we found no significant differences in term of OS between NACT + IDS patients with residual disease = 0 and PDS patients with residual disease = 0 or residual disease = 1, as well as no significant differences in PFS were found comparing NACT + IDS patients with residual disease = 0 and PDS patients with residual disease = 0; contrarily, median PFS resulted significantly lower in PDS patients receiving optimal debulking (residual disease = 1) in comparison to NACT + IDS patients receiving complete debulking (residual disease = 0). PDS arm was affected by a significant higher rate of severe post-operative complications (grade 3 and 4). Diagnostic laparoscopy before surgery was significantly associated with complete debulking. Conclusions We confirm previous findings concerning the non-superiority of NACT + IDS compared to PDS for the treatment of EOC, even if NACT + IDS treatment was associated with significant lower rate of post-operative complications. On the other hand, selecting patients for NACT + IDS, based on laparoscopic evaluation of resectabilty prolongs the PFS and does not worse the OS compared to the patients not completely debulked with PDS." @default.
• W2890802034 created "2018-09-27" @default.
• W2890802034 creator A5010597317 @default.
• W2890802034 creator A5027617351 @default.
• W2890802034 creator A5049534450 @default.
• W2890802034 creator A5050260629 @default.
• W2890802034 creator A5055702066 @default.
• W2890802034 creator A5062897203 @default.
• W2890802034 creator A5068780239 @default.
• W2890802034 creator A5071158373 @default.
• W2890802034 creator A5077454618 @default.
• W2890802034 creator A5079395328 @default.
• W2890802034 date "2018-09-01" @default.
• W2890802034 modified "2023-10-17" @default.
• W2890802034 title "Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals" @default.
• W2890802034 cites W1152011753 @default.
• W2890802034 cites W1413021352 @default.
• W2890802034 cites W1569243391 @default.
• W2890802034 cites W1964736695 @default.
• W2890802034 cites W1989331806 @default.
• W2890802034 cites W1989526666 @default.
• W2890802034 cites W2005222102 @default.
• W2890802034 cites W2009097203 @default.
• W2890802034 cites W2017567241 @default.
• W2890802034 cites W2038209588 @default.
• W2890802034 cites W2039785378 @default.
• W2890802034 cites W2061036783 @default.
• W2890802034 cites W2090095614 @default.
• W2890802034 cites W2101646591 @default.
• W2890802034 cites W2106767659 @default.
• W2890802034 cites W2118060163 @default.
• W2890802034 cites W2144173184 @default.
• W2890802034 cites W2165527456 @default.
• W2890802034 cites W2168893449 @default.
• W2890802034 cites W2223663708 @default.
• W2890802034 cites W2343028883 @default.
• W2890802034 cites W2416210343 @default.
• W2890802034 cites W2434761093 @default.
• W2890802034 cites W2516784158 @default.
• W2890802034 cites W2546926005 @default.
• W2890802034 cites W2554234257 @default.
• W2890802034 cites W2558215838 @default.
• W2890802034 cites W2566120061 @default.
• W2890802034 cites W2570618306 @default.
• W2890802034 cites W2590203295 @default.
• W2890802034 cites W2607612071 @default.
• W2890802034 cites W2608251600 @default.
• W2890802034 cites W966213934 @default.
• W2890802034 doi "https://doi.org/10.2478/raon-2018-0030" @default.
• W2890802034 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6137361" @default.
• W2890802034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30210049" @default.
• W2890802034 hasPublicationYear "2018" @default.
• W2890802034 type Work @default.
• W2890802034 sameAs 2890802034 @default.
• W2890802034 citedByCount "35" @default.
• W2890802034 countsByYear W28908020342019 @default.
• W2890802034 countsByYear W28908020342020 @default.
• W2890802034 countsByYear W28908020342021 @default.
• W2890802034 countsByYear W28908020342022 @default.
• W2890802034 countsByYear W28908020342023 @default.
• W2890802034 crossrefType "journal-article" @default.
• W2890802034 hasAuthorship W2890802034A5010597317 @default.
• W2890802034 hasAuthorship W2890802034A5027617351 @default.
• W2890802034 hasAuthorship W2890802034A5049534450 @default.
• W2890802034 hasAuthorship W2890802034A5050260629 @default.
• W2890802034 hasAuthorship W2890802034A5055702066 @default.
• W2890802034 hasAuthorship W2890802034A5062897203 @default.
• W2890802034 hasAuthorship W2890802034A5068780239 @default.
• W2890802034 hasAuthorship W2890802034A5071158373 @default.
• W2890802034 hasAuthorship W2890802034A5077454618 @default.
• W2890802034 hasAuthorship W2890802034A5079395328 @default.
• W2890802034 hasBestOaLocation W28908020341 @default.
• W2890802034 hasConcept C121608353 @default.
• W2890802034 hasConcept C126322002 @default.
• W2890802034 hasConcept C141071460 @default.
• W2890802034 hasConcept C143998085 @default.
• W2890802034 hasConcept C146357865 @default.
• W2890802034 hasConcept C151730666 @default.
• W2890802034 hasConcept C167135981 @default.
• W2890802034 hasConcept C168563851 @default.
• W2890802034 hasConcept C203092338 @default.
• W2890802034 hasConcept C2776694085 @default.
• W2890802034 hasConcept C2780427987 @default.
• W2890802034 hasConcept C2780435969 @default.
• W2890802034 hasConcept C2781100745 @default.
• W2890802034 hasConcept C50382708 @default.
• W2890802034 hasConcept C71924100 @default.
• W2890802034 hasConcept C86803240 @default.
• W2890802034 hasConceptScore W2890802034C121608353 @default.
• W2890802034 hasConceptScore W2890802034C126322002 @default.
• W2890802034 hasConceptScore W2890802034C141071460 @default.
• W2890802034 hasConceptScore W2890802034C143998085 @default.
• W2890802034 hasConceptScore W2890802034C146357865 @default.
• W2890802034 hasConceptScore W2890802034C151730666 @default.
• W2890802034 hasConceptScore W2890802034C167135981 @default.
• W2890802034 hasConceptScore W2890802034C168563851 @default.
• W2890802034 hasConceptScore W2890802034C203092338 @default.
• W2890802034 hasConceptScore W2890802034C2776694085 @default.

• next